for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.OQ

Latest Trade

324.11USD

Change

-1.87(-0.57%)

Volume

758,984

Today's Range

322.88

 - 

330.58

52 Week Range

215.81

 - 

374.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
325.98
Open
327.20
Volume
758,984
3M AVG Volume
35.79
Today's High
330.58
Today's Low
322.88
52 Week High
374.94
52 Week Low
215.81
Shares Out (MIL)
174.06
Market Cap (MIL)
58,609.09
Forward P/E
--
Dividend (Yield %)
--

Next Event

Biogen Inc at Cowen HealthCare Conference

Latest Developments

More

Berkshire Hathaway Cuts Share Stake In Wells Fargo & Co, Takes Stake in Biogen

Biogen Says Is Pleased With U.S. Patent Trial And Appeal Board’S Decision Upholding U.S. Patent Covering Daily Dosing Regimen Of 480 Mg For Tecfidera

Biogen Says Entered Into Credit Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Contact Info

225 Binney St

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Jeffrey D. Capello

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.66 mean rating - 32 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

12.3K

2018

13.5K

2019

14.4K

2020(E)

14.1K
EPS (USD)

2017

21.810

2018

26.200

2019

33.570

2020(E)

32.547
Price To Earnings (TTM)
10.70
Price To Sales (TTM)
4.08
Price To Book (MRQ)
4.40
Price To Cash Flow (TTM)
9.11
Total Debt To Equity (MRQ)
44.63
LT Debt To Equity (MRQ)
33.42
Return on Investment (TTM)
26.90
Return on Equity (TTM)
22.72

Latest News

Latest News

Buffett's Berkshire buys Kroger and Biogen, reduces Wells Fargo and Goldman stakes

Warren Buffett's Berkshire Hathaway Inc on Friday said it has taken a $549.1 million stake in Kroger Co, investing in the largest U.S. supermarket chain as smaller rivals struggle.

BRIEF-Berkshire Hathaway Cuts Share Stake In Wells Fargo & Co, Takes Stake in Biogen

* BERKSHIRE HATHAWAY CUTS SHARE STAKE IN WELLS FARGO & CO BY 14.6% TO 323.2 MILLION SHARES - SEC FILING

Biogen shares soar 32% on MS drug patent win over Mylan

Biogen Inc's shares surged as much as 32% on Wednesday after the drugmaker won a favorable U.S. patent ruling for its main multiple sclerosis drug Tecfidera in a battle with Mylan NV.

U.S. patent office rules in favor of Biogen over Mylan for MS drug

An administrative court on Wednesday ruled in favor of Biogen Inc in a battle with generic drugmaker Mylan NV over a patent on its multiple sclerosis drug Tecfidera.

Biogen gears up for potential launch of Alzheimer's drug

Biogen Inc said on Thursday it was preparing for the launch of its experimental treatment for Alzheimer's as the drugmaker races to become the first to bring a treatment for the memory-robbing disease to market.

Biogen quarterly profit jumps on demand for multiple sclerosis drug

Drugmaker Biogen Inc reported a 52.1% jump in fourth-quarter profit on Thursday, driven by demand for its top-selling multiple sclerosis drug, Tecfidera, and strength in biosimilars business.

Roche aims to 'underwhelm' on SMA drug price to challenge rivals

Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world's most expensive medicines, Biogen's Spinraza and Novartis's gene therapy Zolgensma.

Biogen scraps development of therapy for rare brain disease

Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a therapy for the disorder.

Biogen halts development of therapy for rare brain disease

Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after it failed a mid-stage trial.

Biogen builds case for its Alzheimer's drug, skeptics say more data needed

Biogen Inc on Thursday laid out more data on its experimental Alzheimer's drug that raised no major safety alarms but also offered little compelling evidence the drug, once declared a failure, actually works.

UPDATE 3-New Biogen data showed no major safety issues for its Alzheimer's drug

Biogen Inc on Thursday presented new data on its experimental Alzheimer's drug aducanumab that eased concerns raised by some experts but still left many questions unanswered as the company made its case about why it plans to seek U.S. approval after declaring the drug a...

Biogen presents new data on its controversial Alzheimer's drug

Biogen Inc on Thursday presented new data from on its experimental Alzheimer's drug aducanumab showing that no patients in a high-risk group that were genetically predisposed to get Alzheimer's died while taking the high dose of the drug, which had been a key concern.

Novartis R&D boss says doesn't see big opportunity in oral SMA therapy

Novartis research head Jay Bradner said on Thursday the Swiss drugmaker is focusing efforts against spinal muscular atrophy (SMA) on gene therapy Zolgensma and retreating from oral therapy like its molecule LMI070, also called branaplam.

Biogen to make case to skeptics for its controversial Alzheimer's drug

Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer's drug aducanumab, which the U.S. biotech company had declared a failure earlier this year.

Roche eyes quick FDA approval in SMA race with Biogen, Novartis

Roche expects its risdiplam medicine for spinal muscular atrophy to get U.S. approval by next May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area.

Roche drug for spinal muscular atrophy hits target in late-stage trial

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.

Roche sets sights on Novartis, Biogen as SMA trial hits target

Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.

Small relief for Biogen in MS drug approval

The U.S. Food and Drug Administration on Wednesday approved Biogen Inc's new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges.

FDA approves multiple sclerosis drug from Biogen and Alkermes

Biogen Inc and partner Alkermes Plc said on Wednesday that the U.S. Food and Drug Administration approved their oral drug to treat multiple sclerosis.

Biogen, Eisai revive plans for Alzheimer's drug, surprising market

Biogen Inc <BIIB.O> revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up